The DDW Turning Science into Business Summit, ‘Cancer research opportunities and advances’ will feature experts and thought leaders in cancer research, precision medicine and immunotherapy.
DDW is delighted to confirm that ICON’s SrVP and Global Head of Science Andreas Dreps and Senior Director Muaiad Kittaneh will present a session on identifying research strategies to get to market faster. The event is sponsored by Taconic Biosciences.
The free two-hour Summit ‘Cancer research opportunities and advances’, hosted by DDW, will take place online on 16 November at 7AM PDT / 10AM EDT / 3PM GMT / 4PM CET.
The presentation will address important issues in antibody drug development, including choosing the right biomarker, drug formulation and manufacturing. They will discuss critical aspects of clinical trial design and leveraging regulatory pathways, in addition to outlining the differences between fast track, break through therapy, priority review regulatory designations and accelerated approval pathways.
Dreps and Kittaneh will also explore the importance of collaboration and data sharing in antibody drug development. Finally, the session will examine the evolving aspects of disruptive technology, machine learning and artificial intelligence to enable the acceleration of oncology drug development.
Dr Kittaneh has more than 15 years’ medical practice experience and was an Associate Professor of Medicine in the Department of Experimental Therapeutics at Karmanos Cancer Institute. Andreas Dreps, PhD, draws on over 25 years’ experience in clinical research and development in a variety of solid tumours and haematology diseases.